InnoBio Gets Backing

InnoBio, a biotech fund managed by CDC Entreprises, and Sofinnova Partners have announced a joint investment in MedDay for 8 million euros ($10.5 million). Created in 2011 by Dr Frédéric Sedel and Dr Guillaume Brion, MedDay is specialised in the treatment of neuro-metabolic diseases.

Siparex Backs Malherbe

Siparex has announced the equity restructuring of Malherbe group, a French five lot and consolidated shipment company. The company’s management, headed by chairman Alain Samson, will be the majority owner, alongside a new group of financial investors comprising Siparex, CDC Entreprises (investing under the FSI France Investissement program), UNEXO, Socadif, and NCI. The fund Siparex MidMarket III is making its debut investment on this deal, in which NiXEN Partners is selling its stake.

DelfMEMS Raises $10.5M From CDC, Iris, Capilalaria, VIVES, Others

DelfMEMS said it raised $10.5 million in Series B funding from CDC Entreprises, Iris Capital, Capitalaria, VIVES as well as existing investors A2D Invest, Alliansys, Finorpa, Inovam, Rhône-Alpes-Création and various angels. The funding will be used to support the company’s growth in MEMS based switching products used as front end wireless modules for mobile devices like smart phones and tablets.

Sofinnova Partners Raises Seventh Life Sciences Fund

Sofinnova Partners has raised 240 million euros ($312 million) for its seventh life sciences venture capital fund. Sofinnova Capital VII‘s investors include leading the European Investment Fund, Skandia Life Insurance Company, CNP Assurances, and CDC Entreprises. Sofinnova Capital VII will invest about two third of its funds in European companies, and one third outside of Europe, most often in the USA.

French Tech Seed Fund has Some $40M to Invest

French venture capital firm Innovacom is managing the investments for French seed fund Technocom 2, an initiative launched by the Fonds National d’Amorçage alongside major French industrial partners Alcatel-Lucent, Orange, Groupe SEB and Soitec.

Cytheris Raises €12 Million

Cytheris SA, a French drug startup focused on immune modulation, has raised €12 million in Series D funding. CDC Entreprises led the round, and was joined by return backers Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity and Forbion Capital Partners.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget